Two AbbVie immunology treatments that were approved last year--Skyrizi and Rinvoq--face tough competition, but they could add $1.7 billion to the top line.AbbVie is working on a number of coronavirus projects, supporting clinical testing of its HIV drug Kaletra and starting a phase 2 study of Imbruvica.